← All drugs
Drug · FAERS side-effect profile with label screen

Folic Acid side effects: what 247,820 FDA adverse event reports show

Folic Acid · 1,191 reaction terms · 1,483,415 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Who reports

247,820 reports · 74% serious · 23,149 with death outcome · 68% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood.

FDA label, Indications and Usage

What it is

Folic acid is an N-acyl-amino acid that is a form of the water-soluble vitamin B9. Its biologically active forms (tetrahydrofolate and others) are essential for nucleotide biosynthesis and homocysteine remethylation.

PubChem CID 135398658 (ChEBI)

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled (related wording) 1Reporting / coding artifact 1Lab value / disease marker 10Not in label — unassessed 28
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,151 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Anti-cyclic citrullinated peptide antibody positive5,560315.2
297.5–333.9ROR 322.4 · calibrated p 5e-12 ✓
66.2 EB05 64.7 · IC025 +6.0
3/3 methods agree
Lab value / disease markerserious PRR 51.5 · ♀ 100% (drug 68%) · 93% cliniciannot reported in cached trials
Anti-cyclic citrullinated peptide antibody497253.0
211.9–302.1ROR 253.5 · calibrated p 6e-11 ✓
62.8 EB05 58.3 · IC025 +5.7
3/3 methods agree
Lab value / disease markerserious n=497 · ♀ 100% (drug 68%) · 100% cliniciannot reported in cached trials
Swollen joint count increased2,292240.2
221.5–260.4ROR 242.4 · calibrated p 7e-11 ✓
62.1 EB05 60.0 · IC025 +5.9
3/3 methods agree
Lab value / disease markerserious n=2,290 · ♀ 100% (drug 68%) · 95% cliniciannot reported in cached trials
Pemphigus9,103237.1
227.7–246.8ROR 246.1 · calibrated p 6e-11 ✓
61.9 EB05 60.9 · IC025 +5.9
3/3 methods agree
Not in label — unassessedserious PRR 48.2 · ♀ 100% (drug 68%)not reported in cached trials
Rheumatic fever3,085207.4
194.1–221.5ROR 210.0 · calibrated p 3e-10 ✓
59.7 EB05 58.0 · IC025 +5.8
3/3 methods agree
Not in label — unassessedserious n=3,084 · ♀ 100% (drug 68%) · 94% cliniciannot reported in cached trials
Deep vein thrombosis postoperative1,349189.6
172.1–208.8ROR 190.6 · calibrated p 6e-10 ✓
58.1 EB05 55.6 · IC025 +5.7
3/3 methods agree
Not in label — unassessedserious n=1,349 · ♀ 100% (drug 68%) · 93% cliniciannot reported in cached trials
Duodenal ulcer perforation5,016185.5
176.5–195.0ROR 189.3 · calibrated p 6e-10 ✓
57.8 EB05 56.4 · IC025 +5.8
3/3 methods agree
Not in label — unassessedserious PRR 44.8 · ♀ 100% (drug 68%) · 93% cliniciannot reported in cached trials
Rheumatoid factor positive3,719155.2
147.0–163.9ROR 157.6 · calibrated p 3e-9 ✓
54.5 EB05 53.0 · IC025 +5.7
3/3 methods agree
Lab value / disease markerserious n=3,716 · ♀ 100% (drug 68%) · 94% cliniciannot reported in cached trials
Lupus vulgaris756148.8
132.1–167.7ROR 149.3 · calibrated p 5e-9 ✓
53.6 EB05 50.5 · IC025 +5.6
3/3 methods agree
Not in label — unassessedserious n=756 · ♀ 100% (drug 68%) · 100% cliniciannot reported in cached trials
C-reactive protein575147.7
128.9–169.4ROR 148.1 · calibrated p 6e-9 ✓
53.5 EB05 49.9 · IC025 +5.5
3/3 methods agree
Lab value / disease markerserious n=574 · ♀ 100% (drug 68%) · 100% cliniciannot reported in cached trials
Hand deformity7,652120.0
115.9–124.2ROR 123.8 · calibrated p 2e-8 ✓
49.5 EB05 48.5 · IC025 +5.6
3/3 methods agree
Not in label — unassessedserious PRR 41.5 · ♀ 98% (drug 68%)not reported in cached trials
Facet joint syndrome1,834118.4
110.2–127.1ROR 119.2 · calibrated p 3e-8 ✓
49.2 EB05 47.3 · IC025 +5.5
3/3 methods agree
Not in label — unassessedserious n=1,831 · ♀ 100% (drug 68%) · 94% cliniciannot reported in cached trials
Adjustment disorder with depressed mood1,00984.8
77.7–92.6ROR 85.2 · calibrated p 4e-7 ✓
42.3 EB05 40.2 · IC025 +5.3
3/3 methods agree
Not in label — unassessedserious n=1,007 · ♀ 100% (drug 68%) · 100% cliniciannot reported in cached trials
Helicobacter infection5,02682.3
79.2–85.6ROR 84.0 · calibrated p 4e-7 ✓
41.7 EB05 40.7 · IC025 +5.3
3/3 methods agree
Not in label — unassessedserious PRR 34.1 · ♀ 100% (drug 68%) · 93% cliniciannot reported in cached trials
Dislocation of vertebra1,02271.8
66.0–78.1ROR 72.1 · calibrated p 1e-6 ✓
38.8 EB05 36.9 · IC025 +5.2
3/3 methods agree
Not in label — unassessedserious n=1,022 · ♀ 100% (drug 68%) · 93% cliniciannot reported in cached trials
X-ray abnormal77865.2
59.4–71.6ROR 65.4 · calibrated p 2e-6 ✓
36.8 EB05 34.7 · IC025 +5.1
3/3 methods agree
Lab value / disease markerserious n=778 · ♀ 100% (drug 68%) · 100% cliniciannot reported in cached trials
Synovitis7,63261.8
60.0–63.7ROR 63.8 · calibrated p 3e-6 ✓
35.8 EB05 35.1 · IC025 +5.1
3/3 methods agree
Not in label — unassessedserious PRR 29.0 · ♀ 95% (drug 68%)not reported in cached trials
Muscle injury3,46161.5
58.9–64.3ROR 62.4 · calibrated p 3e-6 ✓
35.7 EB05 34.7 · IC025 +5.1
3/3 methods agree
Not in label — unassessedserious PRR 29.9 · ♀ 100% (drug 68%) · 94% cliniciannot reported in cached trials
C-reactive protein abnormal2,65759.8
56.9–62.8ROR 60.4 · calibrated p 4e-6 ✓
35.1 EB05 34.0 · IC025 +5.1
3/3 methods agree
Lab value / disease markerserious n=2,656 · ♀ 92% (drug 68%) · 90% cliniciannot reported in cached trials
Sleep disorder due to general medical condition, insomnia type2,60457.3
54.5–60.2ROR 57.9 · calibrated p 5e-6 ✓
34.2 EB05 33.1 · IC025 +5.0
3/3 methods agree
Not in label — unassessedserious n=2,594 · ♀ 100% (drug 68%) · 94% cliniciannot reported in cached trials
Retinitis64653.2
48.2–58.7ROR 53.3 · calibrated p 9e-6 ✓
32.7 EB05 30.6 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious n=645 · ♀ 100% (drug 68%) · 100% cliniciannot reported in cached trials
Folliculitis3,96852.6
50.5–54.7ROR 53.4 · calibrated p 9e-6 ✓
32.5 EB05 31.6 · IC025 +5.0
3/3 methods agree
Not in label — unassessedserious PRR 29.6 · ♀ 100% (drug 68%) · 94% cliniciannot reported in cached trials
Glossodynia (burning tongue/mouth pain)8,54352.1
50.7–53.5ROR 53.9 · calibrated p 8e-6 ✓
32.3 EB05 31.7 · IC025 +5.0
3/3 methods agree
Not in label — unassessedserious PRR 36.0 · ♀ 100% (drug 68%)not reported in cached trials
Pericarditis6,20450.0
48.4–51.5ROR 51.2 · calibrated p 1e-5 ✓
31.5 EB05 30.8 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious PRR 24.6 · ♀ 98% (drug 68%) · 93% cliniciannot reported in cached trials
Peripheral venous disease1,42346.6
43.7–49.7ROR 46.9 · calibrated p 2e-5 ✓
30.1 EB05 28.8 · IC025 +4.8
3/3 methods agree
Not in label — unassessedserious n=1,417 · ♀ 100% (drug 68%) · 91% cliniciannot reported in cached trials
Subcutaneous drug absorption impaired19446.5
39.0–55.5ROR 46.6 · calibrated p 2e-5 ✓
30.0 EB05 26.6 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=193 · ♀ 100% (drug 68%) · 100% cliniciannot reported in cached trials
Blood pressure systolic abnormal84543.2
39.8–47.0ROR 43.4 · calibrated p 3e-5 ✓
28.7 EB05 27.1 · IC025 +4.7
3/3 methods agree
Lab value / disease markerserious n=828not reported in cached trials
Blood pressure diastolic abnormal85341.8
38.5–45.4ROR 41.9 · calibrated p 4e-5 ✓
28.1 EB05 26.5 · IC025 +4.7
3/3 methods agree
Lab value / disease markerserious n=832not reported in cached trials
Red blood cell sedimentation rate abnormal75140.1
36.7–43.7ROR 40.2 · calibrated p 5e-5 ✓
27.3 EB05 25.7 · IC025 +4.6
3/3 methods agree
Lab value / disease markerserious n=747 · ♀ 92% (drug 68%)not reported in cached trials
Seronegative arthritis34537.3
32.8–42.3ROR 37.3 · calibrated p 8e-5 ✓
26.0 EB05 23.7 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=342 · ♀ 100% (drug 68%) · 100% cliniciannot reported in cached trials
Bone erosion1,02134.0
31.6–36.6ROR 34.1 · calibrated p 1e-4 ✓
24.4 EB05 23.1 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=1,018 · ♀ 93% (drug 68%)not reported in cached trials
Systemic lupus erythematosus10,17533.9
33.2–34.7ROR 35.3 · calibrated p 1e-4 ✓
24.3 EB05 23.9 · IC025 +4.6
3/3 methods agree
Not in label — unassessedage-adj. PRR 26.7 · serious PRR 19.3 · ♀ 98% (drug 68%)not reported in cached trials
Wound7,52931.2
30.4–32.0ROR 32.1 · calibrated p 2e-4 ✓
22.9 EB05 22.5 · IC025 +4.5
3/3 methods agree
Not in label — unassessedage-adj. PRR 22.3 · serious PRR 20.9 · ♀ 96% (drug 68%)not reported in cached trials
Granuloma skin21228.9
24.7–33.7ROR 28.9 · calibrated p 3e-4 ✓
21.6 EB05 19.3 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=209 · ♀ 100% (drug 68%) · 100% cliniciannot reported in cached trials
Contraindicated product administered7,31026.8
26.2–27.6ROR 27.6 · calibrated p 4e-4 ✓
20.5 EB05 20.1 · IC025 +4.3
3/3 methods agree
Reporting / coding artifactage-adj. PRR 19.4 · serious PRR 19.7 · ♀ 97% (drug 68%)not reported in cached trials
Joint destruction36225.3
22.5–28.4ROR 25.3 · calibrated p 7e-4 ✓
19.6 EB05 17.9 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=358 · ♀ 100% (drug 68%) · 100% cliniciannot reported in cached trials
Enthesopathy35624.4
21.7–27.5ROR 24.5 · calibrated p 8e-4 ✓
19.1 EB05 17.5 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=352 · 100% cliniciannot reported in cached trials
Breast cancer stage iii1,44324.3
22.9–25.7ROR 24.4 · calibrated p 8e-4 ✓
19.0 EB05 18.2 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=1,443 · ♀ 100% (drug 68%) · 94% cliniciannot reported in cached trials
Grip strength decreased1,87022.8
21.7–24.0ROR 23.0 · calibrated p 0.001 ✓
18.1 EB05 17.4 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=1,822 · ♀ 93% (drug 68%)not reported in cached trials

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Liver injury12,5833.63.6–3.7signal
Interstitial lung disease3,8733.53.4–3.6signal
Serious infection25,8062.92.9–2.9signal
Anaemia9,9792.92.8–2.9signal
Tendon disorder1,2212.82.6–2.9signal
Opportunistic infection3,8782.42.4–2.5signal
Fall / fracture9,8962.22.2–2.3signal
Thrombocytopenia4,8501.91.8–1.9raised
Gi bleeding3,9001.81.8–1.9raised
Hyperglycaemia / diabetes7,3211.81.8–1.8raised
Hyponatraemia1,6871.81.7–1.9raised
Depression5,7461.71.7–1.8raised
Venous thromboembolism4,1551.61.6–1.7raised
Kidney injury8,4311.61.5–1.6raised
Pancreatitis1,3871.51.4–1.5raised
Neutropenia / agranulocytosis4,2351.51.4–1.5raised

Trial evidence (ClinicalTrials.gov)

✓ Trial adverse-event data found on ClinicalTrials.gov

Largest completed trials with posted results that list Folic Acid as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (0 of 40 signal terms matched).

Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug ineffective (drug did not work)25,2661.6
1.6–1.7ROR 1.7 · calibrated p 0.774
1.6 EB05 1.6 · IC025 +0.7Reporting / coding artifactage-adj. PRR 1.8 · serious PRR 2.8not reported in cached trials
Fatigue (tiredness)23,9192.7
2.6–2.7ROR 2.8 · calibrated p 0.683
2.6 EB05 2.6 · IC025 +1.4
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.2 · serious PRR 3.1not reported in cached trials
Pain23,6173.3
3.3–3.4ROR 3.6 · calibrated p 0.464
3.2 EB05 3.2 · IC025 +1.7
3/3 methods agree
Not in label — unassessedage-adj. PRR 3.1 · serious PRR 3.4NCT00124072: 156/6,033 (2.6%) on Folic Acid; 154/6,031 (2.6%) control
Arthralgia (joint pain)19,9914.2
4.2–4.3ROR 4.5 · calibrated p 0.293
4.1 EB05 4.0 · IC025 +2.0
3/3 methods agree
Not in label — unassessedage-adj. PRR 3.7 · serious PRR 4.8not reported in cached trials
Off label use (used outside approved label)18,0701.8
1.8–1.8ROR 1.8 · calibrated p 0.853
1.8 EB05 1.7 · IC025 +0.8Reporting / coding artifactage-adj. PRR 1.7 · serious PRR 2.2not reported in cached trials
Rheumatoid arthritis17,93715.8
15.6–16.0ROR 17.0 · calibrated p 0.004 ✓
13.4 EB05 13.3 · IC025 +3.7
3/3 methods agree
Not in label — unassessedage-adj. PRR 12.9 · serious PRR 11.9 · ♀ 89% (drug 68%)not reported in cached trials
Nausea16,0441.7
1.7–1.8ROR 1.8 · calibrated p 0.822
1.7 EB05 1.7 · IC025 +0.8Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 2.0not reported in cached trials
Headache14,6002.0
2.0–2.0ROR 2.1 · calibrated p 0.976
2.0 EB05 1.9 · IC025 +1.0Not in label — unassessedage-adj. PRR 1.8 · serious PRR 2.4not reported in cached trials
Diarrhoea (diarrhea)14,5991.9
1.9–2.0ROR 2.0 · calibrated p 0.944
1.9 EB05 1.9 · IC025 +0.9Not in label — unassessedage-adj. PRR 1.8 · serious PRR 2.0not reported in cached trials
Rash14,0222.8
2.7–2.8ROR 2.9 · calibrated p 0.659
2.7 EB05 2.7 · IC025 +1.4
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.5 · serious PRR 4.0not reported in cached trials
Dyspnoea (shortness of breath)13,6552.1
2.0–2.1ROR 2.1 · calibrated p 0.986
2.0 EB05 2.0 · IC025 +1.0
3/3 methods agree
Not in label — unassessedage-adj. PRR 1.8 · serious PRR 2.0not reported in cached trials
Abdominal discomfort11,9796.5
6.3–6.6ROR 6.7 · calibrated p 0.110
6.1 EB05 6.0 · IC025 +2.6
3/3 methods agree
Not in label — unassessedage-adj. PRR 4.8 · serious PRR 9.8 · ♀ 91% (drug 68%)not reported in cached trials
Alopecia (hair loss)11,9285.4
5.3–5.5ROR 5.6 · calibrated p 0.177
5.1 EB05 5.1 · IC025 +2.3
3/3 methods agree
Not in label — unassessedage-adj. PRR 3.9 · serious PRR 7.8 · ♀ 98% (drug 68%)not reported in cached trials
Joint swelling11,7949.1
8.9–9.3ROR 9.5 · calibrated p 0.038 ✓
8.3 EB05 8.2 · IC025 +3.0
3/3 methods agree
Not in label — unassessedage-adj. PRR 7.5 · serious PRR 10.1 · ♀ 89% (drug 68%)not reported in cached trials
Condition aggravated11,4813.3
3.2–3.4ROR 3.4 · calibrated p 0.505
3.2 EB05 3.2 · IC025 +1.7
3/3 methods agree
Reporting / coding artifactage-adj. PRR 3.0 · serious PRR 3.5not reported in cached trials

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Zoledronic acid (bisphosphonates) ↔ Osteonecrosis of the jaw.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Folic Acid?

In FDA FAERS, the most frequently co-reported reaction terms for Folic Acid are fatigue, pain, arthralgia, rheumatoid arthritis, nausea, headache. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Folic Acid have an FDA boxed warning?

No. The FDA label retrieved for Folic Acid has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Folic Acid causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.